Login

Call for Grant Applications (CGA) Understanding Oncology Clinical Trial Outcomes and Comparative Assessment

10 May 2017 3:46 PM | Jim Ranieri (Administrator)

Date CGA Issued: May 9, 2017

Clinical Area: Oncology Outcomes & Evidence

Link to full CGA:Understanding Oncology Clinical Trial Outcomes and Comparative Assessment

Due Date: June 21, 2017

Specific Area of Interest: It is our intent to support continuing professional development programs (CME/CE) for managed care decision-makers, formulary decision-makers, other payor decision-makers, pharmacists/pharmacy directors, and medical oncologists/medical directors. Proposed programs should focus on increasing the understanding of one or more of the following topics, in order of priority:

1.    Formulary Class Review & Considerations: Examining Current and Emerging Agents in the CDK 4/6 Inhibitor Class for the Treatment of HER2(-)/ER(+) Advanced or Metastatic Breast Cancer

2.    The use of Patient Reported Outcomes (PROs) in Oncology Versus Other Therapeutic Areas and a Primer for Payers to the PRO-Common Terminology Criteria for Adverse Events Tool (PRO-CTCAE tool)

3.    Application & Limitations of Evidenced-Based Methods for Indirect Treatment & Trials Comparisons: Value frameworks (ASCO Value Framework, NCCN Evidence Blocks, etc) and Real World Data for indirect treatment comparisons; and Network Meta-Analysis (NMA), Simulated Treatment Comparison (STC), Match Adjusted Treatment Comparison (MAIC), etc. for indirect trials comparisons

4.    Challenges with Oncology Trial Design/Approvals & Endpoints in Value Assessment

Questions regarding this CGA should be directed to derek.warnick@pfizer.com.


Powered by Wild Apricot Membership Software